Clinical Cases in Pharmacology Clinical Cases  ·  Endocrinology, Diabetes and Metabolism III  ·  Pituitary  ·  Hypogonadotropic Hypogonadism — Fertility-Desiring Patient
Endocrinology, Diabetes and Metabolism III, Case EndoPituitary-0010 — Pituitary

He Wants Testosterone Fixed and a Baby Both — Only One Drug Does Both

A single patient, hypogonadotropic hypogonadism confirmed after pituitary surgery, wanting both symptom relief and a chance at fathering a child in the next year. The disagreement is whether the conventional first-line treatment is actually first-line for him at all.

Abbreviations, terms, and other agents mentioned in this case LH/FSH — luteinizing hormone / follicle-stimulating hormone  ·  hCG — human chorionic gonadotropin
Presentation

J.H., a 33-year-old man, works as a high school shop teacher, a job he loves and one that has made the fatigue and low libido that brought him in feel more like a personal failure than a medical finding, since he's used to being the guy who can outwork his students on a project all afternoon. A 24mm nonfunctioning macroadenoma was resected four months ago; postoperative testing confirmed hypogonadotropic hypogonadism — testosterone 142 ng/dL with inappropriately low-normal LH and FSH rather than the elevated gonadotropins that would indicate primary testicular failure, consistent with his pituitary disease as the cause rather than a separate testicular problem. He and his wife have been trying to conceive for eight months without success, a timeline that predates his surgery and diagnosis, and he raises fatherhood in the same breath as his fatigue, clearly having thought about both as one problem rather than two separate ones.

They are not, pharmacologically, one problem, and the distinction matters more here than in almost any other hormone-replacement decision in this clinic. Exogenous testosterone is the standard, effective treatment for his biochemical hypogonadism and would resolve his fatigue and libido symptoms reliably — but it works by directly supplying the hormone his pituitary should be signaling his testes to make, which further suppresses his already-low LH and FSH and, with it, the intratesticular testosterone concentration spermatogenesis actually depends on, concentrations roughly a hundredfold higher locally than anything achieved systemically. Men on standard testosterone replacement become, in the overwhelming majority of cases, azoospermic within months — testosterone therapy is a reliable male contraceptive by mechanism, not a side effect anyone intends, and starting it now would directly work against the second thing he's asking for in the same visit as the first.

J.H. · 33 4 months post-op
History
Nonfunctioning macroadenoma, resected 4 months ago
Testosterone
142 ng/dL — low
LH/FSH
Low-normal — inappropriate for his low testosterone, confirms central cause
Semen analysis, baseline
Oligospermia, consistent with hypogonadotropic state
Fertility goal
Actively trying to conceive with his wife for 8 months
Other axes
Cortisol and thyroid replacement stable

The standard fix for his labs is the one thing he can't have right now

Endocrinologist Opening

Standard testosterone replacement is off the table for him right now, even though it's what his labs alone would normally call for. Exogenous testosterone suppresses his already-low LH and FSH further, which drops intratesticular testosterone — the concentration that actually drives spermatogenesis, roughly a hundredfold higher than anything a systemic dose achieves — and the overwhelming majority of men on standard replacement become azoospermic within months. Starting it now would actively work against the second thing he's asking for today.

Reproductive Endocrinologist Response

Agreed on avoiding testosterone, and I'd start hCG rather than wait to see if his fertility timeline changes. hCG mimics LH directly, stimulating his own Leydig cells to produce testosterone intratesticularly at the concentration spermatogenesis needs, which both raises his systemic testosterone toward normal and, unlike exogenous testosterone, supports rather than suppresses sperm production.

The honest tradeoff he needs to hear clearly: hCG alone restores spermatogenesis in a majority of men with hypogonadotropic hypogonadism, but not universally, and response can take several months to become apparent in semen parameters — this isn't the fast symptom relief testosterone would offer, and he should understand that going in, not discover it three months from now feeling like the plan failed.

Endocrinologist Final

That's the conversation I'd want to have with him directly today — hCG first, with FSH added if semen parameters at three months show inadequate spermatogenic response despite testosterone normalizing on hCG alone, since some men need the added FSH signal specifically for full spermatogenesis rather than just Leydig-cell testosterone production. And I'd be explicit that this is a fertility-preserving strategy with real published success rates, not a compromise he's making by avoiding the more familiar drug.

Regimen selected
Human Chorionic Gonadotropin (hCG)
LH-Receptor Agonist · Subcutaneous, 2-3 times weekly
Stimulates endogenous intratesticular testosterone production directly, raising systemic testosterone while supporting rather than suppressing spermatogenesis.
Recombinant FSH — Held in Reserve
FSH-Receptor Agonist · Contingent on semen analysis at 3 months
Added if hCG alone doesn't produce adequate spermatogenic response; some men require the additional FSH signal beyond Leydig-cell stimulation alone.
Exogenous Testosterone — Explicitly Avoided
Androgen Replacement · Not started while fertility is being pursued
Would resolve his symptoms reliably but suppresses spermatogenesis in the large majority of men through gonadotropin suppression — directly counter to his stated goal.
Where this was left

Agreed: start hCG, with an explicit plan to add FSH at three months if semen analysis shows inadequate improvement despite testosterone normalizing on hCG alone. Testosterone replacement is deferred entirely while fertility remains an active goal, with the tradeoff — slower symptom relief in exchange for preserved fertility potential — explained to J.H. directly as a real strategy with published success, not a fallback.

Both physicians converged quickly once the mechanism was laid out; the reproductive endocrinologist's addition was ensuring the timeline and non-universal response rate were disclosed clearly enough that a slow first few months doesn't read to J.H. as treatment failure.

Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →